A 7 cm breast tumor is classified as T3 in the staging system used by oncologists, meaning it is larger than 5 cm across. Based on tumor size alone, it falls into at least Stage IIB, but the final stage depends heavily on whether cancer has reached nearby lymph nodes, whether it has spread to distant organs, and the tumor’s biological characteristics.
How a 7 cm Tumor Is Classified by Size
Breast cancer staging uses a system called TNM: T for tumor size, N for lymph node involvement, and M for distant metastasis. A tumor over 5 cm is categorized as T3. That puts a 7 cm tumor solidly in this category, well above the 5 cm threshold. However, if the tumor has grown into the chest wall or skin, it would be reclassified as T4 regardless of size, which changes the staging picture entirely.
The Stage Depends on More Than Size
Tumor size is only one piece of the puzzle. A 7 cm tumor with no lymph node involvement and no distant spread (T3 N0 M0) is typically at least Stage IIB based on anatomy alone. If cancer has reached nearby lymph nodes, the stage moves higher, potentially into Stage IIIA or beyond. And if cancer has spread to distant sites like the bones, lungs, liver, or brain, the diagnosis becomes Stage IV, no matter how large or small the original tumor is.
What makes breast cancer staging especially complex is that since 2018, the staging system used in the U.S. also factors in the tumor’s biology. Three characteristics matter: whether the tumor has hormone receptors (estrogen and progesterone), whether it overproduces a growth protein called HER2, and how abnormal the cells look under a microscope (the tumor’s grade). These biological details can shift the final stage dramatically.
For example, a 7 cm tumor with no lymph node spread that is low-grade, hormone receptor-positive, and HER2-positive could be staged as low as Stage IB. The same size tumor that is high-grade, hormone receptor-negative, and HER2-negative could be classified as Stage IIIB. Same tumor size, vastly different stages. This is why two people with 7 cm tumors can receive very different stage designations and very different treatment plans.
What Imaging and Testing to Expect
When a tumor is this large, your oncology team will want to determine whether cancer has spread beyond the breast. For smaller, early-stage tumors, full-body imaging scans are generally not recommended because the chance of finding distant spread is low. But for locally advanced disease, which a 7 cm tumor often qualifies as, imaging to check for metastasis is more commonly considered. This may include CT scans of the chest and abdomen, a bone scan, or a PET-CT, though the exact approach varies by institution and whether you have any symptoms suggesting spread.
A biopsy of the tumor will also provide the biological details (hormone receptor status, HER2 status, and grade) needed to finalize your stage. If lymph nodes appear enlarged on imaging, they may be biopsied as well.
Treatment Usually Starts Before Surgery
For a 7 cm breast tumor, treatment often begins with chemotherapy, hormone therapy, or targeted therapy before any surgery. This approach, called neoadjuvant therapy, has several practical goals. Shrinking the tumor first can make surgery less extensive, sometimes allowing a lumpectomy instead of a full mastectomy. It also gives doctors a real-time window into how well the cancer responds to a particular treatment. If the tumor shrinks significantly or disappears entirely, that’s valuable information for planning what comes next.
For tumors that respond to hormones (estrogen or progesterone receptor-positive), hormone-blocking therapy before surgery can produce response rates similar to chemotherapy, particularly in postmenopausal women. However, completely eliminating the tumor with this approach alone is rare. For HER2-positive tumors, targeted therapies are typically added to chemotherapy, which tends to produce stronger responses.
Surgical Options for Large Tumors
A mastectomy (removing the entire breast) is more common with tumors this size, but it is not always the only option. If neoadjuvant treatment shrinks the tumor enough, breast-conserving surgery (lumpectomy followed by radiation) may become feasible. The decision depends on how much the tumor shrinks relative to your breast size, whether cancer is present in more than one area of the breast, and your own preferences. If the remaining breast would look significantly different after a lumpectomy, or if you cannot receive radiation therapy, mastectomy is typically the recommended path.
Survival and Outlook
A 7 cm tumor is large, but size alone does not determine outcome. The tumor’s biology, its grade, and whether it has reached lymph nodes or distant organs all play major roles. For breast cancers that have spread to regional lymph nodes but not to distant organs (the category many large tumors fall into), the five-year relative survival rate is about 87.5%, based on recent data from the national SEER cancer database. That number reflects a broad mix of tumor types and treatments, so individual outcomes can be better or worse depending on the specific biology involved.
Tumors that are hormone receptor-positive and lower grade tend to have a more favorable outlook, even at larger sizes. Triple-negative tumors (negative for estrogen receptors, progesterone receptors, and HER2) generally carry a higher risk, though newer treatment combinations have improved outcomes for this subtype as well. Your oncologist will use all of these factors together, not just tumor size, to give you the most accurate picture of your prognosis.